Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of RO7790121 induction therapy in moderate to severe active ulcerative colitis
CTR20244624Phase 3Active
- Sponsor
- Roche
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of afimkibart, sponsored by Roche. Started Mar 2026; status: active.
02
Drugs
afimkibart
Beyond the preview
Go deeper on CTR20244624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244624.